Name: UMIN ID:
Unique ID issued by UMIN | UMIN000009886 |
---|---|
Receipt number | R000011539 |
Scientific Title | Study on the clinical efficacy of Eribulin as the first- or second-line treatment in patients with recurrent HER2- negative breast cancer (randomized Phase II study)(JBCRG-19) |
Date of disclosure of the study information | 2013/02/01 |
Last modified on | 2021/06/29 14:39:42 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2013/01/28 16:22:10 | ||
2 | Update | 2013/06/14 16:27:45 | Recruitment status |
|
3 | Update | 2013/07/29 10:48:02 | Institutions |
|
4 | Update | 2013/12/06 13:50:11 | Email |
|
5 | Update | 2013/12/06 14:01:48 | Public title Public title |
|
6 | Update | 2013/12/06 14:18:43 | Condition Condition Narrative objectives1 Narrative objectives1 Key secondary outcomes Key secondary outcomes |
|
7 | Update | 2013/12/06 15:03:37 | Key inclusion criteria Key inclusion criteria |
|
8 | Update | 2014/07/29 09:50:06 | Interventions/Control_2 |
|
9 | Update | 2014/07/29 09:55:35 | Address Address TEL Address Address TEL Institutions |
|
10 | Update | 2014/07/29 09:57:20 | Last follow-up date |
|
11 | Update | 2014/09/10 14:14:40 | Public title |
|
12 | Update | 2014/09/10 14:16:26 | Public title |
|
13 | Update | 2014/09/10 14:18:19 | Condition Narrative objectives1 |
|
14 | Update | 2014/09/10 14:30:14 | Key inclusion criteria Target sample size |
|
15 | Update | 2014/09/10 14:31:00 | Last follow-up date |
|
16 | Update | 2014/09/17 10:22:30 | Public title |
|
17 | Update | 2014/09/17 10:23:21 | Condition Narrative objectives1 |
|
18 | Update | 2014/09/17 10:39:18 | Key inclusion criteria |
|
19 | Update | 2015/07/28 10:50:34 | Institutions |
|
20 | Update | 2016/02/02 14:06:39 | Last follow-up date |
|
21 | Update | 2016/07/08 15:39:17 | Recruitment status |
|
22 | Update | 2016/07/08 15:40:05 | Name of primary person or sponsor Organization |
|
23 | Update | 2018/02/01 09:09:49 | Recruitment status |
|
24 | Update | 2018/08/23 15:15:16 | Recruitment status Last follow-up date |
|
25 | Update | 2018/08/24 10:07:56 | UMIN ID1 |
|
26 | Update | 2019/03/28 16:21:14 | Recruitment status Date of IRB Anticipated trial start date Last follow-up date |
|
27 | Update | 2019/09/05 14:53:49 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Address Last name of contact person Last name of contact person Zip code Address Address Organization Organization Address Address Tel |
|
28 | Update | 2019/09/05 14:56:26 | Number of participants that the trial has enrolled |
|
29 | Update | 2021/06/25 15:56:09 | Last name of contact person Last name of contact person Homepage URL Name of person sending information Name of person sending information |
|
30 | Update | 2021/06/29 14:39:42 | URL releasing protocol Publication of results URL related to results and publications Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |